Vacuolar H+-ATPase (V-ATPase)

Vacuolar H+-ATPase (V-ATPase) is a highly conserved, multi-subunit enzyme that functions as an ATP-driven rotary proton pump across biological membranes [1, 2]. It is primarily responsible for the acidification of intracellular compartments, such as endosomes, lysosomes, and the Golgi apparatus, which is essential for processes like protein degradation, membrane trafficking, and nutrient sensing [3, 6]. In specialized cells, V-ATPases are also localized to the plasma membrane, where they facilitate extracellular acidification for bone resorption by osteoclasts and urinary acidification by renal intercalated cells [1, 3]. Dysregulation of V-ATPase is implicated in various pathologies, including cancer, where it promotes tumor invasion and drug resistance, and osteoporosis, where it drives excessive bone loss [4, 9]. Pharmacological targeting of V-ATPase has focused on small-molecule inhibitors like bafilomycin and concanamycin, though their clinical utility is limited by systemic toxicity due to the pump's essential housekeeping roles [5, 7]. Recent therapeutic strategies aim for isoform-specific inhibition or disrupting the pump's interaction with the cytoskeleton to achieve better selectivity [4, 16]. Additionally, V-ATPase plays a critical role in the entry of several viruses and bacterial toxins by providing the acidic environment required for membrane fusion or translocation [3, 12]. The complex consists of a peripheral V1 domain for ATP hydrolysis and an integral V0 domain for proton transport, which are regulated by reversible dissociation [1, 10]. Mutations in specific V-ATPase subunits are linked to genetic disorders such as distal renal tubular acidosis and osteopetrosis [1, 3]. Overall, V-ATPase represents a versatile and essential molecular machine with significant potential as a drug target if selectivity challenges can be overcome [4, 7].

Other names

Vacuolar-type H+-transporting ATPaseV-type ATPaseH+-transporting ATPaseVacuolar proton pumpV-type proton pump

V-ATPase inhibitors primarily act by binding to the V0 domain, particularly the c-subunit proteolipid ring, to block the rotary mechanism of proton translocation [1, 11]. Other mechanisms include preventing the reversible assembly of the V1 and V0 domains or disrupting the interaction between the V-ATPase complex and the actin cytoskeleton, thereby inhibiting its recruitment to the plasma membrane [4, 16].